A targeted proteomics-based pipeline for verification of biomarkers in plasma.


High-throughput technologies can now identify hundreds of candidate protein biomarkers for any disease with relative ease. However, because there are no assays for the majority of proteins and de novo immunoassay development is prohibitively expensive, few candidate biomarkers are tested in clinical studies. We tested whether the analytical performance of a biomarker identification pipeline based on targeted mass spectrometry would be sufficient for data-dependent prioritization of candidate biomarkers, de novo development of assays and multiplexed biomarker verification. We used a data-dependent triage process to prioritize a subset of putative plasma biomarkers from >1,000 candidates previously identified using a mouse model of breast cancer. Eighty-eight novel quantitative assays based on selected reaction monitoring mass spectrometry were developed, multiplexed and evaluated in 80 plasma samples. Thirty-six proteins were verified as being elevated in the plasma of tumor-bearing animals. The analytical performance of this pipeline suggests that it should support the use of an analogous approach with human samples.


The following biomarkers make reference to this publication:

  • Amon L
  • Chodosh LA
  • Gafken PR
  • Hogan JM
  • Hou L
  • Jones LA
  • Kelly-Spratt KS
  • Kemp CJ
  • Kennedy J
  • Krasnoselsky A
  • Lin C
  • McIntosh MW
  • Nelson PS
  • Paulovich AG
  • Schoenherr RM
  • Sokal I
  • Trute M
  • Voytovich UJ
  • Wang P
  • Whiteaker JR
  • Yan P
  • Zhao L
PubMed ID
Appears In
Nat Biotechnol, 2011, 29 (7)